Our study shows the feasibility and reproducibility to expand NPM1mut-specific CTLs on a GMP scale from AML patients in hematologic remission, but also from healthy donors, by stimulation with DCs pulsed with a peptide pool derived from the mutated NPM1 antigen, irrespective of the donor HLA type. This evidence concerns the gene NPM1 and acute myeloid leukemia.